The Proteinase Activated Receptor 2 pipeline drugs market research report outlays comprehensive information on the Proteinase Activated Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Proteinase Activated Receptor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Central Nervous System, Gastrointestinal, and Immunology which include the indications Asthma, Unspecified Respiratory Disorders, Migraine, Unspecified Neurologic Disorders, Inflammatory Bowel Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Psoriasis, and Unspecified Immunological Disorders. It also reviews key players involved in Proteinase Activated Receptor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Proteinase Activated Receptor 2 pipeline targets constitutes close to 15 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 4, 4, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Proteinase Activated Receptor 2 overview
Protease activated receptor 2 (PAR2) also known as coagulation factor II (thrombin) receptor-like 1 (F2RL1) is a protein encoded by the F2RL1 gene. PARs (protease-activated receptors) are G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. PAR2 plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2.
For a complete picture of Proteinase Activated Receptor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
